Preterm birth and PROM Testing Market Size 2022-2030, Market Share Analysis, Growth, Trends, Covid 19 Outbreak Impact Research Report Added by Precedence Research.
The preterm birth and PROM testing market size was estimated at US$ 1.66 billion in 2021 and is projected to reach US$ 2.21 billion by 2030 at a CAGR of 3.2% from 2022 to 2030.
The report contains 150+ pages with detailed analysis. The base year for the study has been considered 2021, the historic year 2017 to 2020, the forecast period considered is from 2022 to 2030.
Download FREE Sample of This Strategic Report with TOC, Graphs & List of Figures @ https://www.precedenceresearch.com/sample/1281
Preterm birth simply refers to premature birth or birth before the completion of 37 weeks of pregnancy. This is a major cause of death among the children of 5 years. Preterm born babies are prone to malnutrition, underweight, and weak immunity. The preterm birth and PROM testing is an effective tool to detect the preterm birth symptoms in women and helps in preventing preterm births.As per the data published by the WHO, around 15 million babies are born preterm annually across the world. Preterm birth and PROM testing help to detect the premature rapture of fetal membranes in pregnant women. By detecting the raptured fetal membrane, the patient can be treated and prevent the preterm birth. Hence, the growing cases of preterm birth and growing rate of death among children is a primary driver of the global market.
Crucial factors accountable for market growth are:
- Rising cases of preterm birth across the world
- Growing penetration of diagnostic labs and healthcare centers
- Rising awareness regarding the preterm birth and PROM testing availability
- Point of Care test is gaining traction
- Technological advancements in the PROM testing tools
- Growing penetration of online consultation of doctors or telemedicine
Scope of the Preterm Birth and PROM Testing Market
| Report Highlights | Details |
| Market Size | USD 2.21 Billion by 2030 |
| Growth Rate | CAGR of 3.2% From 2022 to 2030 |
| Base Year | 2020 |
| Historic Data | 2017 to 2020 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Test Type, End User |
| Regional Scope | North America, APAC, Europe, Latin America, MEAN, Rest of the World |
Market Dynamics
Driver
The primary driver of the preterm birth and PROM testing market is the growing cases of premature birth and increasing death among children due to preterm birth. The adoption of point of care tests is gaining immense traction as it is inexpensive, reliable, and accurate. The rising penetration of internet has fueled the growth of telemedicine. Therefore, through online doctor consultation, the symptoms of preterm birth can be detected earlier and PROM tests can be conducted for early identification and treatment of the patient. This will act as a key driver in the upcoming years.
Restraints
The lack of awareness regarding preterm births, availability of PROM testing services, and low disposable income in underdeveloped and developing countries is a major restraint that may hamper the market growth during the forecast period.
Opportunities
Asia Pacific to provide lucrative growth opportunities owing to the rapidly growing population in countries like India and China. According to UNICEF, around 25 million births each year is recorded in India and the death rate is 35% due to the preterm birth. Thus Asia Pacific is expected to show a promising growth rate in the market.
Challenges
Lack of diagnostic centers and adequate number of health care centers in the rural areas of developing and underdeveloped countries remains an untapped market. These markets have a great growth potential because maximum population resides in rural areas especially in developing countries.
Report Highlights
- Ultrasound segment led the global preterm birth and PROM testing market with 32% revenue share in 2020. This is attributed to the fact that ultrasound is the most common, reliable, and painless way of PROM testing.
- By end user, diagnostic laboratories segment held 45% revenue share in the global preterm birth and PROM testing market in 2020 owing to the higher demand and the growing penetration in the developed markets.
- North America dominated the global market in 2020 and projected to augment the market in the coming years due to the growing cases of preterm birth rate in U.S. According to CDC (Centers for Disease Control and Prevention), 10% of the babies born in 2019 in US were born preterm. Around 17% of the preterm babies die due to low birth weight.
- Asia Pacific is fastest growing market owing to the rising awareness regarding preterm birth. According to the WHO, over 60% of the preterm birth cases occurs in Africa and South Asia. The rapid development of healthcare facilities in Asia is a factor that is anticipated to be the driving force of the market.
Competitive Intelligence
The preterm birth and PROM testing market report provides an understanding of the market composition and explains the role of established players and regional contributors. It is essential for the market players to make calculative moves and focus on client acquisition and retention. The detailed company profiles will provide the necessary intelligence to the reader. In order to maintain their share, the market players are focusing on strategies such as cross-border expansion, product differentiation, and so on.
Some of the key players in the global preterm birth and PROM testing market include:
- Abbott
- Qiagen N.V.
- Biosynex
- Hologic
- Cooper Surgical
- Sera Prognostics
- Medixbiochemica
- IQ Products
- NX Prenatal, Inc.
- Clinical Innovations, Inc.
Segments Covered in the Report
By Test Type
- Ultrasound
- Biochemical Markers
- Pelvic Exam
- Nitazine Test
- Uterine Monitoring
- Pooling
- Ferning Test
- Others
By End User
- Diagnostic Laboratories
- Hospitals
- Others
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of the World
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Preterm Birth and PROM Testing Market, By Test
7.1. Preterm Birth and PROM Testing Market, by Test Type, 2021-2030
7.1.1. Ultrasound
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Biochemical Markers
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Pelvic Exam
7.1.3.1. Market Revenue and Forecast (2017-2030)
7.1.4. Nitazine Test
7.1.4.1. Market Revenue and Forecast (2017-2030)
7.1.5. Uterine Monitoring
7.1.5.1. Market Revenue and Forecast (2017-2030)
7.1.6. Pooling
7.1.6.1. Market Revenue and Forecast (2017-2030)
7.1.7. Ferning Test
7.1.7.1. Market Revenue and Forecast (2017-2030)
7.1.8. Others
7.1.8.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Preterm Birth and PROM Testing Market, By End User
8.1. Preterm Birth and PROM Testing Market, by End User, 2021-2030
8.1.1. Diagnostic Laboratories
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Hospitals
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Preterm Birth and PROM Testing Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, by Test (2017-2030)
9.1.2. Market Revenue and Forecast, by End User (2017-2030)
9.1.3. U.S.
9.1.3.1. Market Revenue and Forecast, by Test (2017-2030)
9.1.3.2. Market Revenue and Forecast, by End User (2017-2030)
9.1.4. Rest of North America
9.1.4.1. Market Revenue and Forecast, by Test (2017-2030)
9.1.4.2. Market Revenue and Forecast, by End User (2017-2030)
9.2. Europe
9.2.1. Market Revenue and Forecast, by Test (2017-2030)
9.2.2. Market Revenue and Forecast, by End User (2017-2030)
9.2.3. UK
9.2.3.1. Market Revenue and Forecast, by Test (2017-2030)
9.2.3.2. Market Revenue and Forecast, by End User (2017-2030)
9.2.4. Germany
9.2.4.1. Market Revenue and Forecast, by Test (2017-2030)
9.2.4.2. Market Revenue and Forecast, by End User (2017-2030)
9.2.5. France
9.2.5.1. Market Revenue and Forecast, by Test (2017-2030)
9.2.5.2. Market Revenue and Forecast, by End User (2017-2030)
9.2.6. Rest of Europe
9.2.6.1. Market Revenue and Forecast, by Test (2017-2030)
9.2.6.2. Market Revenue and Forecast, by End User (2017-2030)
9.3. APAC
9.3.1. Market Revenue and Forecast, by Test (2017-2030)
9.3.2. Market Revenue and Forecast, by End User (2017-2030)
9.3.3. India
9.3.3.1. Market Revenue and Forecast, by Test (2017-2030)
9.3.3.2. Market Revenue and Forecast, by End User (2017-2030)
9.3.4. China
9.3.4.1. Market Revenue and Forecast, by Test (2017-2030)
9.3.4.2. Market Revenue and Forecast, by End User (2017-2030)
9.3.5. Japan
9.3.5.1. Market Revenue and Forecast, by Test (2017-2030)
9.3.5.2. Market Revenue and Forecast, by End User (2017-2030)
9.3.6. Rest of APAC
9.3.6.1. Market Revenue and Forecast, by Test (2017-2030)
9.3.6.2. Market Revenue and Forecast, by End User (2017-2030)
9.4. MEA
9.4.1. Market Revenue and Forecast, by Test (2017-2030)
9.4.2. Market Revenue and Forecast, by End User (2017-2030)
9.4.3. GCC
9.4.3.1. Market Revenue and Forecast, by Test (2017-2030)
9.4.3.2. Market Revenue and Forecast, by End User (2017-2030)
9.4.4. North Africa
9.4.4.1. Market Revenue and Forecast, by Test (2017-2030)
9.4.4.2. Market Revenue and Forecast, by End User (2017-2030)
9.4.5. South Africa
9.4.5.1. Market Revenue and Forecast, by Test (2017-2030)
9.4.5.2. Market Revenue and Forecast, by End User (2017-2030)
9.4.6. Rest of MEA
9.4.6.1. Market Revenue and Forecast, by Test (2017-2030)
9.4.6.2. Market Revenue and Forecast, by End User (2017-2030)
9.5. Latin America
9.5.1. Market Revenue and Forecast, by Test (2017-2030)
9.5.2. Market Revenue and Forecast, by End User (2017-2030)
9.5.3. Brazil
9.5.3.1. Market Revenue and Forecast, by Test (2017-2030)
9.5.3.2. Market Revenue and Forecast, by End User (2017-2030)
9.5.4. Rest of LATAM
9.5.4.1. Market Revenue and Forecast, by Test (2017-2030)
9.5.4.2. Market Revenue and Forecast, by End User (2017-2030)
Chapter 10. Company Profiles
10.1. Abbott
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. Qiagen N.V.
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Biosynex
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Hologic
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. Cooper Surgical
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Sera Prognostics
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. Medixbiochemica
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. IQ Products
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. NX Prenatal, Inc.
10.9.1. Company Overview
10.9.2. Product Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
10.10. Clinical Innovations, Inc.
10.10.1. Company Overview
10.10.2. Product Offerings
10.10.3. Financial Performance
10.10.4. Recent Initiatives
Chapter 11. Research Methodology
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
Chapter 12. Appendix
12.1. About Us
12.2. Glossary of Terms
Purchase Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1281
About Us
Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.
Contact Us:
Precedence Research
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Address: Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada